A practice-based approach to the 2012 position statement of the American Diabetes Association and the European Association for the Study of Diabetes

被引:6
作者
Schwartz, Stanley S. [1 ,2 ]
机构
[1] Main Line Hlth Syst, Bryn Mawr, PA USA
[2] Univ Penn, Philadelphia, PA 19104 USA
关键词
ADA/EASD position statement; Cardiovascular risk; Clinical management; Patient centered; Type 2 diabetes mellitus; CARDIOVASCULAR-DISEASE; HEPATIC IMPAIRMENT; RISK; EVENTS; PHARMACOKINETICS; METAANALYSIS; MORTALITY; METFORMIN; BROMOCRIPTINE; HYPERGLYCEMIA;
D O I
10.1185/03007995.2013.798637
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The position statement on the management of hyperglycemia in patients with type 2 diabetes mellitus issued in 2012 by the American Diabetes Association and the European Association for the Study of Diabetes contains significant improvements over the 2009 version, including an emphasis on patient-centered care, enhanced strategies for lifestyle modification, a focus on comprehensive cardiovascular risk reduction, and increased pharmacotherapy choices. As diabetes management evolves over time, further improvements may be made in future consensus statements, including a focus on prevention and early treatment and improved glycemic control in all patients, including those with comorbidities. These goals will be achievable by waning use of therapies known to cause hypoglycemia and weight gain and the increased use of therapies that do not carry these risks.
引用
收藏
页码:793 / 799
页数:7
相关论文
共 41 条
  • [1] *AM PHARM INC, 2011, BYETT EX FULL PRESCR
  • [3] [Anonymous], 2012, DIABETES CARE, V35, pS11, DOI [10.2337/dc35-S011, 10.2337/dc12-s004]
  • [4] [Anonymous], 2009, BMJ, DOI DOI 10.1136/BMJ.B4731
  • [5] [Anonymous], 2012, TRADJ LIN FULL PRESC
  • [6] [Anonymous], 2012, JAN SIT FULL PRESCR
  • [7] COLESEVELAM HYDROCHLORIDE ADDED TO BACKGROUND METFORMIN THERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A POOLED ANALYSIS FROM 3 CLINICAL STUDIES
    Bays, Harold E.
    [J]. ENDOCRINE PRACTICE, 2011, 17 (06) : 933 - 938
  • [8] Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies A retrospective analysis of the LifeLink database
    Best, Jennie H.
    Hoogwerf, Byron J.
    Herman, William H.
    Pelletier, Elise M.
    Smith, Daniel B.
    Wenten, Made
    Hussein, Mohamed A.
    [J]. DIABETES CARE, 2011, 34 (01) : 90 - 95
  • [9] Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Saxagliptin
    Boulton, David W.
    Li, Li
    Frevert, Ernst U.
    Tang, Angela
    Castaneda, Lorna
    Vachharajani, Nimish N.
    Kornhauser, David M.
    Patel, Chirag G.
    [J]. CLINICAL PHARMACOKINETICS, 2011, 50 (04) : 253 - 265
  • [10] *BRIST SQUIBB CO, 2011, ONGL SAX FULL PRESCR